|
OMNICOMM SYSTEMS, INC. ENTERS INTO AN ENTERPRISE
ELECTRONIC DATA CAPTURE (EDC) AGREEMENT WORTH
$8-10 MILLION WITH A MAJOR BIOTECHNOLOGY COMPANY
Company continues to expand its footprint by providing leading-edge, integrated EDC
solutions and services to its rapidly growing customer base
FT. LAUDERDALE, FL – May 19, 2008 – /MarketWire/ - OmniComm Systems, Inc.
(OTC Bulletin Board: OMCM.OB), a leader in integrated electronic data capture (EDC)
solutions for clinical trials, today announced that the company has entered into a 5-year,
multi-million dollar enterprise agreement with a major west coast biotechnology
company. The agreement allows the biotech company to take full advantage of
OmniComm’s First in Functionality™, EDC solution, TrialMaster™ for up to 10
concurrent trials per year. The biotech company will strategically utilize OmniComm’s
EDC application to assist in managing their global clinical trials and clinical related data.
The enterprise deal includes complete licensing, services and technical support for these
10 concurrent studies. The agreement also provides for an option to exceed 10
concurrent studies per year for a predetermined ‘per study’ price.
“Of course we are very excited to be chosen by such a prestigious company to manage
their clinical trials over the next 5 years.” said Stephen Johnson, Chief Operating Officer
of OmniComm. “Their commitment to us is matched only by our commitment to our
customers to deliver best of breed solutions that integrate seamlessly into their clinical
environment. And we back this up with industry leading customer service & support
teams.”
OmniComm is committed to providing their customers with comprehensive, world-class
customer service and support. A key component of OmniComm’s service offering is a
dedicated Clinical Services division that provides its customers with extensive clinical
trial industry experience. This team of industry professionals oversees the database
creation and data dictionary design process and offers a variety of consulting services
including protocol design, process revision and FDA submission services as part of the
study build process. OmniComm also offers a comprehensive learning environment that
includes Instructor led, live or web-based training, eLearning, train-the-trainer or a
customized approach that is designed for the clients’ specific needs.
About OmniComm
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet
solutions to pharmaceutical, biotechnology, research and medical device organizations
that conduct life changing clinical trial research. OmniComm’s growing base of satisfied
customers is a direct result of the company’s commitment to deliver products and
services that ensure ease of use, faster study build, ease of integration and better
performance. OmniComm’s client intuitive pricing model allows companies that range
from small to mid-size to large scale institutions to safely and efficiently capitalize on
their clinical research investments. OmniComm Systems, Inc. has corporate headquarters
in Ft. Lauderdale, Florida with offices in Bonn, Germany, Tula, Russia, California,
Maryland, New York, North Carolina and Texas.
Safe Harbor Disclaimer
Statements about OmniComm’s future expectations, including without limitation, future
revenues and earnings, plans and objectives for the future operations, future agreements,
future economic performance, operations and all other statements in this press release
other than historical facts are "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of
1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995.
OmniComm intends that such forward-looking statements be subject to the Safe Harbors
created thereby. Since these statements involve risks and uncertainties, including but not
limited to economic competitive, governmental, contractual and technological factors
affecting OmniComm’s operations, markets and profitability, actual results could differ
materially and adversely from the expected results.
CONTACT:
Lizanne Kelley
OmniComm Systems, Inc.
954-473-1254 Extension 283
lkelley@omnicomm.com
Back |
